Invention Grant
- Patent Title: Compounds for enzyme inhibition
-
Application No.: US13334263Application Date: 2011-12-22
-
Publication No.: US08207124B2Publication Date: 2012-06-26
- Inventor: Mark S. Smyth , Guy J. Laidig
- Applicant: Mark S. Smyth , Guy J. Laidig
- Applicant Address: US CA South San Francisco
- Assignee: Onyx Therapeutics, Inc.
- Current Assignee: Onyx Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Fish & Richardson P.C.
- Main IPC: A61K38/07
- IPC: A61K38/07 ; C07K1/00 ; C07K5/00

Abstract:
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Public/Granted literature
- US20120094928A1 COMPOUNDS FOR ENZYME INHIBITION Public/Granted day:2012-04-19
Information query
IPC分类: